Onychomycosis Market Report and Forecast 2024-2032

Onychomycosis Market Report and Forecast 2024-2032


Onychomycosis Market Outlook

The onychomycosis market size was valued at USD 4 billion in 2023, driven by prevalence of onychomycosis and related conditions. The market size is anticipated to grow at a CAGR of 5.2% during the forecast period of 2024-2032 to achieve a value of USD 6.3 billion by 2032.

Onychomycosis: Introduction

Onychomycosis is a fungal infection that primarily affects the toenails and, less frequently, the fingernails. It is characterized by changes in nail color, thickness, and texture, often resulting in yellow, brittle, or thickened nails. The condition is caused by various fungi, with dermatophytes being the most common culprits. It is more prevalent in older adults and can be exacerbated by factors like diabetes, weakened immune systems, and poor circulation. Onychomycosis is not just a cosmetic issue; it can lead to discomfort and pain, particularly when wearing shoes, and can also spread to other nails or skin. Treatment often involves antifungal medications, either topical or oral, and can take several months for complete nail recovery.

Key Trends in the Onychomycosis Market

The growth of the onychomycosis market is largely driven by the rising incidence of the condition and increased awareness about its treatment. The infection's impact on social and psychological well-being emphasizes the need for effective treatments. Organizations like the Global Nail Fungus Organization and government initiatives like the CDC's "Think Fungus" campaign are working to increase awareness and improve prevention and treatment strategies, which in turn is boosting the demand for onychomycosis therapeutics.

Drugs remain the primary choice for onychomycosis treatment due to their high success rate. Commonly used drugs include terbinafine, ciclopirox, Jublia, and Fluconazole. The market is expected to continue favouring drugs due to their effectiveness and accessibility. Notably, new drugs are being approved, such as Tavaborole Topical Solution by Lupin, enhancing treatment options.

The distal subungual onychomycosis segment has been particularly dominant, likely due to its increasing prevalence and the number of generic drug approvals by regulatory agencies like the FDA. On the other hand, the topical treatment segment is expected to witness the fastest growth, attributed to the ease of use and administration, leading to higher patient compliance.

Pharmaceutical companies are focusing on acquiring specialized capabilities and forming strategic collaborations and partnerships to develop novel therapies for onychomycosis. This includes efforts to improve patient compliance and reduce therapy costs, as seen with the launch of highly bioavailable formulations like Intas Pharmaceuticals' Super Bioavailable Itraconazole. Such initiatives are crucial in maintaining competitive positions in the market and addressing specific treatment concerns.

The onychomycosis treatment market is fragmented and highly competitive, with major players like Bausch Health, Galderma SA, Novartis, and Pfizer playing significant roles. These companies focus on development, collaboration, and product launches to strengthen their market positions. For example, the FDA's expanded approval of Jublia by Bausch Health for treating onychomycosis indicates ongoing efforts to enhance treatment options.

Global Onychomycosis Market Segmentation

Market Breakup by Treatment Type
  • Drugs
  • Laser Therapy
  • Photodynamic Therapy
  • Others
Market Breakup by Type
  • Distal Subungual Onychomycosis
  • White Superficial Onychomycosis
  • Proximal Subungual Onychomycosis
  • Other Types
Market Breakup by Route of Administration
  • Oral
  • Topical
Market Breakup by End User
  • Hospitals
  • Dermatology and Podiatry Clinics
  • Offline Pharmacies
  • Online Stores
Market Breakup by Region
  • United States
  • EU-4 and the United Kingdom
Germany

France

Italy

Spain

United Kingdom
  • Japan
Onychomycosis Market Overview

North America, particularly the United States, holds a substantial market share. Factors contributing to this include high drug costs, a growing elderly population, and an increasing number of onychomycosis and diabetic patients. Age-related factors like nail trauma and poor circulation contribute to the prevalence of onychomycosis in this region. The market dynamics have been influenced by strategies like research and development, mergers, acquisitions, and new product launches by major pharmaceutical companies.

Europe, including the United Kingdom and the EU-4 countries (Germany, France, Italy, and Spain), is expected to see significant growth in the onychomycosis market. This growth is attributed to favorable health reimbursement policies, high-quality healthcare infrastructure, and an increasing geriatric population, which is more susceptible to onychomycosis. The European market is also characterized by ongoing research and development in the field of onychomycosis treatments.

The onychomycosis market in Japan is part of the broader Asia-Pacific market, which is emerging rapidly. This growth is driven by increasing awareness, improving healthcare infrastructure, and rising investments in healthcare. The Asia-Pacific region, including Japan, is expected to show significant growth in the onychomycosis market, owing to these factors.

Onychomycosis Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Cipla Inc.
  • Bayer AG
  • Pfizer Inc.
  • Abbott
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Bausch Health Companies Inc.
  • GSK Plc.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

*Please Note:* The report will take 7 business days to complete, after order confirmation.


1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Onychomycosis Disease Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Onychomycosis Disease Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.1 Germany Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.2 France Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.3 Italy Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.4 Spain Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Onychomycosis Disease Epidemiology Forecast (2017-2032)
5.4 Japan Onychomycosis Disease Epidemiology Forecast (2017-2032)
6 Onychomycosis Market Overview – 7MM
6.1 Onychomycosis Market Historical Value (2017-2023)
6.2 Onychomycosis Market Forecast Value ( 2024-2032)
7 Onychomycosis Market Landscape – 7MM
7.1 Onychomycosis: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Onychomycosis: Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Diagnosis Method
8 Onychomycosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Onychomycosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Onychomycosis Market Segmentation – 7MM
11.1 Onychomycosis Market by Treatment Type
11.1.1 Market Overview
11.1.2 Drugs
11.1.3 Laser Therapy
11.1.4 Photodynamic Therapy
11.1.5 Others
11.2 Onychomycosis Market by Type
11.2.1 Market Overview
11.2.2 Distal Subungual Onychomycosis
11.2.3 White Superficial Onychomycosis
11.2.4 Proximal Subungual Onychomycosis
11.2.5 Other Types
11.3 Onychomycosis Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Topical
11.4 Onychomycosis Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Dermatology and Podiatry Clinics
11.4.4 Offline Pharmacies
11.4.5 Online Stores
11.5 Onychomycosis Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Onychomycosis Market
12.1 Onychomycosis Market Historical Value (2017-2023)
12.2 Onychomycosis Market Forecast Value (2024-2032)
12.3 Onychomycosis Market by Type
12.4 Onychomycosis Market by Treatment Type
13 EU-4 and United Kingdom Onychomycosis Market
13.1 Onychomycosis Market Historical Value (2017-2023)
13.2 Onychomycosis Market Forecast Value (2024-2032)
13.3 Germany Onychomycosis Market Overview
13.3.1 Onychomycosis Market by Type
13.3.2 Onychomycosis Market by Treatment Type
13.4 France Onychomycosis Market Overview
13.4.1 Onychomycosis Market by Type
13.4.2 Onychomycosis Market by Treatment Type
13.5 Italy Onychomycosis Market Overview
13.5.1 Onychomycosis Market by Type
13.5.2 Onychomycosis Market by Treatment Type
13.6 Spain Onychomycosis Market Overview
13.6.1 Onychomycosis Market by Type
13.6.2 Onychomycosis Market by Treatment Type
13.7 United Kingdom Onychomycosis Market Overview
13.7.1 Onychomycosis Market by Type
13.7.2 Onychomycosis Market by Treatment Type
14 Japan Onychomycosis Market
14.1 Onychomycosis Market Historical Value (2017-2023)
14.2 Onychomycosis Market Forecast Value (2024-2032)
14.3 Onychomycosis Market by Type
14.4 Onychomycosis Market by Treatment Type
14.5 Onychomycosis Market by Region
14.5.1 Market Overview
14.5.2 United States
14.5.3 EU-4 and the United Kingdom
14.5.3.1 Germany
14.5.3.2 France
14.5.3.3 Italy
14.5.3.4 Spain
14.5.3.5 United Kingdom
14.5.4 Japan
15 United States Onychomycosis Market
15.1 Onychomycosis Market Historical Value (2017-2023)
15.2 Onychomycosis Market Forecast Value (2024-2032)
15.3 Onychomycosis Market by Type
15.4 Onychomycosis Market by Treatment Type
16 EU-4 and United Kingdom Onychomycosis Market
16.1 Onychomycosis Market Historical Value (2017-2023)
16.2 Onychomycosis Market Forecast Value (2024-2032)
16.3 Germany Onychomycosis Market Overview
16.3.1 Onychomycosis Market by Type
16.3.2 Onychomycosis Market by Treatment Type
16.4 France Onychomycosis Market Overview
16.4.1 Onychomycosis Market by Type
16.4.2 Onychomycosis Market by Treatment Type
16.5 Italy Onychomycosis Market Overview
16.5.1 Onychomycosis Market by Type
16.5.2 Onychomycosis Market by Treatment Type
16.6 Spain Onychomycosis Market Overview
16.6.1 Onychomycosis Market by Type
16.6.2 Onychomycosis Market by Treatment Type
16.7 United Kingdom Onychomycosis Market Overview
16.7.1 Onychomycosis Market by Type
16.7.2 Onychomycosis Market by Treatment Type
17 Japan Onychomycosis Market
17.1 Onychomycosis Market Historical Value (2017-2023)
17.2 Onychomycosis Market Forecast Value (2024-2032)
17.3 Onychomycosis Market by Type
17.4 Onychomycosis Market by Treatment Type
18 Regulatory Framework
18.1 Regulatory Overview
18.1.1 US FDA
18.1.2 EU EMA
18.1.3 INDIA CDSCO
18.1.4 JAPAN PMDA
18.1.5 Others
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding and Investment Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Supplier Landscape
22.1 Merck & Co., Inc.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Teva Pharmaceutical Industries Ltd.
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 Cipla Inc.
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 Bayer AG
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Pfizer Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Abbott
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Novartis AG
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Sun Pharmaceutical Industries Ltd.
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Bausch Health Companies Inc.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 GSK Plc.
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
23 Onychomycosis - Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings